Healthcare impact of personalized medicine using genetic testing: An exploratory analysis for warfarin

Personalized Medicine

Volumn 5, Issue 3, 2008, Pages 279-284

  McWilliam, Andrew ^a   Lutter, Randall ^a   Nardinelli, Clark ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bleeding complications; Genetic based therapy; Healthcare costs; Personalized medicine; Warfarin

Indexed keywords

WARFARIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEASIBILITY STUDY; GASTROINTESTINAL HEMORRHAGE; GENE THERAPY; GENETIC SCREENING; GENOTYPE; HEALTH CARE COST; HOSPITAL COST; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; MORTALITY; OPTIMAL DRUG DOSE; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE;

EID: 44949151100     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.3.279     Document Type: Article

References (19)

1. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7, 99-111 (2007).
2. Ansell J, Hirsh J, Dalen J et al.: Managing oral anticoagulant therapy. Chest 119, S22-S38 (2001).
3. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
4. Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
5. Sanderson S, Emery J, Higgins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet™ systematic review and meta-analysis. Genet. Med. 7, 97-104 (2005).
6. Verispan LLC: Vector One® National - True Patient Measures, 2002-2006. Data Extracted (2007).
7. Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, Klungel OH: CYP2C9 genotyping in aceocoumorol treatment: is it a cost effective addition to international normalized ratio monitoring?. Clin. Pharmacol. Ther. 79, 511-520 (2006).
8. You JHS, Chan FWH, Wong RSM, Cheng G: The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb Haemost. 92, 590-597 (2004).
9. Anderson JL, Benjamin DR, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007).
10. Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2007).
11. Hillman MA, Wilke RA, Yale SH et al.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3, 137-145 (2005).
12. Sconce EA, Tayyaba IK, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
13. Linkins L-A, Choi PT, Douketis J: Clinical impact of bleeding in patients tasking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann. Intern. Med. 139, 893-900 (2003).
14. Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ: Major bleeding complications in a specialized anticoagulation service. Am. J. Cardiol. 96, 595-598 (2005).
15. Bureau of Labor Statistics: Consumer Price Index for Medical Care, 2002-2006. Bureau of Labour Statistics, Washington DC, USA (2007).
16. National Center for Health Statistics: Health, United States, 2005. Chart book on Trends in the Health of Americans. National Center for Health Statistics, Hyattsville, MD, USA (2005).
17. Reynolds MW, Fahrbach K, Rauch O et al.: Warfarin anticoagulation and outcomes in patients with atrial fibrillation; a systematic review and meta-analysis. Chest 126, 1938-1945 (2004).
18. Agency for Healthcare Research and Quality (AHRQ): Weighted national estimates from HCUP Nationwide Inpatient Sample (NIS). AHRQ, MD, USA (2002).
19. Taylor TN, Davis PH, Torner JC et al.: Lifetime cost of stroke in the United States. Stroke 27, 1459-1466 (1996).